In this article we will discuss Olaparib (Description-21). So, let’s get started.
PAOLA-1 (NCT02477644) was a randomized, double-blind, placebo-controlled, multi-center trial that
compared the efficacy of Olaparib in combination with bevacizumab versus placebo/bevacizumab for the
maintenance treatment of advanced high-grade epithelial ovarian cancer, fallopian tube or primary
peritoneal cancer following first-line platinum-based chemotherapy and bevacizumab. Randomization
was stratified by first-line treatment outcome (timing and outcome of cytoreductive surgery and response
to platinum-based chemotherapy) and tBRCAm status, determined by prospective local testing. All
available clinical samples were retrospectively tested with Myriad myChoice® CDx.